Current Synthetic and Systems Biology
ISSN: 2332-0737
OPEN ACCESS Freely available online
Short Communication

The Advancing Drug Discovery for Next-Generation Screening Platforms in Cell Culture

Jonathan Charles*

Department of Biology, Reichman University, Herzliya, Israel

DESCRIPTION

Drug discovery is a complex and time-consuming process, often requiring the screening of large compound libraries to identify potential candidates for therapeutic intervention. Traditional screening methods, while effective, are limited by their throughput, cost, and relevance to human physiology. However, with advancements in cell culture technology, the landscape of drug discovery is rapidly evolving towards the development of next-generation screening platforms that promise to revolutionize the field. This article discusses about the future of drug discovery through the lens of creative screening platforms in cell culture, highlighting their potential to accelerate the identification and development of novel therapeutics.

High-throughput screening in cell culture

High Throughput Screening (HTS) has long been a cornerstone of drug discovery, enabling the rapid testing of thousands to millions of compounds for biological activity. Traditionally performed using cell-based assays in microplate formats, HTS has evolved to incorporate advanced automation, robotics, and imaging technologies, significantly increasing throughput and efficiency. With the advent of next-generation screening platforms in cell culture, researchers can now conduct HTS campaigns using Three-Dimensional (3D) cell models, organoids, and patient-derived cells, providing more physiologically relevant data and improving the predictive value of screening assays [1].

Advantages of next-generation screening platforms in cell culture

Improved physiological relevance: Next-generation screening platforms in cell culture, such as organ-on-a-chip systems and patient-derived cell models, offer more physiologically relevant environments compared to traditional Two-Dimensional (2D) cell cultures. This improved relevance allows for better prediction of drug responses and toxicity in human tissues [2].

Enhanced predictive value: By using cell culture models that closely mimic human physiology, next-generation screening platforms provide more accurate predictions of drug efficacy, toxicity, and side effects. This helps to reduce the failure rates of drug candidates in clinical trials by identifying potential issues earlier in the drug discovery process.

Personalized medicine: Patient-derived cell models, such as induced Pluripotent Stem Cells (iPSCs), enable the development of personalized medicine approaches. These models allow for the screening of drugs in cells derived from individual patients, advancing the selection of adaptive treatment regimens based on the patient's unique genetic makeup and disease profile [3,4].

High throughput: Many next-generation screening platforms in cell culture are compatible with High Throughput Screening (HTS) techniques, allowing for the rapid screening of large compound libraries. This increased throughput accelerates the drug discovery process and enables the testing of a wider range of potential drug candidates.

Reduction of animal testing: By using cell culture models instead of animal models, next-generation screening platforms in cell culture offer a more ethical and human approach to drug discovery. This reduction in animal testing aligns with regulatory efforts to minimize the use of animals in research while still ensuring the safety and efficacy of new drug [5].

Techniques of next-generation screening platforms in cell culture

Organ-on-a-chip technology: Organ-on-a-chip platforms use microfluidic systems to culture cells in Three-Dimensional (3D) environments that mimic the structure and function of human organs. These platforms allow for the study of complex tissue interactions and responses to drugs *in vitro*.

Induced Pluripotent Stem Cells (iPSCs): iPSCs are generated by reprogramming adult cells to a pluripotent state, allowing them to differentiate into various cell types. iPSC technology enables the creation of patient-specific cell models for disease modeling, drug screening, and personalized medicine.

Correspondence to: Jonathan Charles, Department of Biology, Reichman University, Herzliya, Israel, E-mail: charlesjo@gmail.com

Received: 26-Feb-2024, Manuscript No. CSSB-24-31589; **Editor assigned:** 29-Feb-2024, PreQC No. CSSB-24-31589 (PQ); **Reviewed:** 14-Mar-2024, QC No. CSSB-24-31589; **Revised:** 21-Mar-2024, Manuscript No. CSSB-24-31589 (R); **Published:** 28-Mar-2024, DOI: 10.35248/2332-0737.24.12.063

Citation: Charles J (2024) The Advancing Drug Discovery for Next-Generation Screening Platforms in Cell Culture. J Curr Synth Syst Bio. 12:063.

Single-cell analysis: Single-cell analysis techniques, such as single-cell RNA sequencing and mass cytometry, allow researchers to analyze the gene expression, protein levels, and metabolites of individual cells within a population. This approach provides insights into cellular heterogeneity and enables the identification of rare cell populations with unique drug responses [6,7].

High-content imaging: High-content imaging systems combine automated microscopy with image analysis algorithms to quantitatively assess cellular phenotypes and responses to drugs. These systems allow for the screening of compounds based on complex cellular features, such as morphology, protein expression, and subcellular localization.

Artificial intelligence and machine learning: Artificial Intelligence (AI) and Machine Learning (ML) algorithms are increasingly being applied to analyze large datasets generated from screening assays. These algorithms can identify patterns and relationships in the data, predict drug responses, and prioritize lead compounds for further investigation [8].

Microfluidic assays: Microfluidic devices enable the precise manipulation of small volumes of liquids and cells, allowing for the development of miniaturized screening assays. These assays can be used to study cell-cell interactions, drug diffusion kinetics, and other dynamic processes *in vitro* [9].

The future of drug discovery lies at the intersection of innovative screening platforms and cell culture technology. By leveraging advanced techniques such as organ-on-a-chip, induced pluripotent stem cells, single-cell analysis, and artificial intelligence, researchers can interrogate complex biological systems with unprecedented precision and throughput. These next-generation screening platforms hold the potential to accelerate the discovery and development of novel therapeutics, transform precision medicine approaches, and ultimately improve patient outcomes across a wide range of diseases and disorders. As we continue to push the boundaries of innovation in drug discovery, the integration of cutting-edge technologies with cell culture-based screening platforms promises to usher in a new era of precision medicine and personalized healthcare [10].

REFERENCES

1. Endo A, Kuroda M, Tsujita Y. ML-236A, ML-236B, and ML-236C, new inhibitors of cholesterogenesis produced by *Penicillium citrinum*. J Antibiot. 1976; 29(12):1346-1348.
2. Kurumbail RG, Kiefer JR, Marnett LJ. Cyclooxygenase enzymes: Catalysis and inhibition. Curr Opin Struct Biol. 2001;11(6): 752-760.
3. Dunaway-Mariano D. Enzyme function discovery. Structure. 2008;16(11):1599-1600.
4. Chen LH, Kenyon GL, Curtin F, Harayama S, Bembenek ME, Hajipour GH, Whitman CP. 4-Oxalocrotonate tautomerase, an enzyme composed of 62 amino acid residues per monomer. J Biol Chem. 1992;267(25):17716-17721.
5. Hubscher U, Shevelev IV. The 3'5'exonucleases. Nat Rev Mol Cell Biol. 2002;3(5):364-376.
6. Zenkin N, Yuzenkova Y, Severinov K. Transcript-assisted transcriptional proofreading. Science. 2006;313(5786):518-520.
7. Bajpai P. Application of enzymes in the pulp and paper industry. Biotechnology progress. 1999; 15(2):147-157.
8. Ramanathan A, Savol A, Burger V, Chennubhotla CS, Agarwal PK. Protein conformational populations and functionally relevant substates. Acc Chem Res. 2014;47(1):149-156.
9. Jorgensen WL. Rusting of the lock and key model for protein-ligand binding. Science. 1991;254(5034):954-955.
10. Fieker A, Philpott J, Armand M. Enzyme replacement therapy for pancreatic insufficiency: Present and future. Clin Exp Gastroenterol. 2011;4:55-73.